
|Articles|February 25, 2021
Pharmacy Practice in Focus: Oncology
- February 2021
- Volume 3
- Issue 1
CE: Innovations in Acute Graft-Versus-Host Disease: Pharmacy Updates on Risk Assessment, Prevention, and Treatment
This activity is supported by an educational grant from Incyte Corporation.
Advertisement
This activity is supported by an educational grant from Incyte Corporation.
EDUCATIONAL OBJECTIVES
At the completion of this activity, the participant will be able to:
- Apply risk scoring tools for assessing grade and stage of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (HSCT) recipients
- Examine emerging strategies in the prevention and treatment of aGVHD
- Maximize the role of the pharmacist of the HSCT team to improve patient outcomes
FACULTY
Nicole Watts, PharmD, BCOP
Clinical Pharmacy Specialist, Blood and Bone Marrow Transplant , University of Alabama at Birmingham Hospital , Birmingham, Alabama
TARGET AUDIENCE: Pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: November 30, 2020
EXPIRATION DATE: August 30, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 2 hours
FEE: This lesson is offered for free at
Articles in this issue
over 5 years ago
Oncology Care Pharmacy Has Promising Trends on the Horizonover 5 years ago
Utilizing Pharmacogenomics Information to Guide AML TreatmentAdvertisement
Related to this article

Extended INDIGO and FIREFLY-1 results presented at SNO 2026 put seizure burden during vorasidenib therapy and time off tovorafenib in pediatric low-grade glioma into focus.

Pharmacists can use medication therapy management to screen for diabetes, educate patients about medication adherence and lifestyle modifications, and support early action.

Higher doses of injectable semaglutide have been shown to cause greater weight loss than standard doses with a similar safety profile.

A transplant pharmacist looks at what azacitidine plus venetoclax’s event-free survival advantage over intensive chemotherapy means for induction selection, and why it doesn’t yet replace 7+3 or CPX-351.

Early germline BRCA testing identifies patients with metastatic pancreatic adenocarcinoma who can be considered for olaparib maintenance if their disease has not progressed after at least 16 weeks of first-line platinum chemotherapy.

In every practice setting, pharmacists can meet vaccine hesitancy with evidence, effective communication, and vetted resources that move patients toward “yes.”

A new US consensus on pancreatic enzyme replacement therapy in pancreatic cancer highlights how pharmacists can counsel patients on taking enzymes with food, check response early, and address barriers to filling the prescription.
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA-1283 Associated With Lower Risk of Medically Attended COVID-19 Than BNT162b2 in Older Veterans
2
Long-Acting HIV Injectables in Viremia and New Tenofovir-Free Oral Options
3
What Pharmacists Should Know About Transitioning Patients to Buprenorphine
4
Two-Drug HIV Regimens, Archived M184V Resistance, and Long-Acting Preference
5
